Study of PRO 140 SC As Single Agent Maintenance Therapy in Virally Suppressed Subjects with CCR5-tropic HIV-1 Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

556 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-11

Study Completion Date

2020-12-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a Phase 2b/3, multi-center study designed to evaluate the efficacy, safety, and tolerability of the strategy of shifting clinically stable patients receiving suppressive combination antiretroviral therapy to PRO 140 monotherapy and maintaining viral suppression for 48 weeks following study entry.

Consenting patients will be shifted from combination antiretroviral regimen to weekly PRO 140 monotherapy for 48 weeks during the Treatment Phase with the one week overlap of existing retroviral regimen and PRO 140 at the beginning of the study treatment and also one week overlap at the end of the treatment in subjects who do not experience virologic failure.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Randomized, Double-Blind, Placebo-Controlled Trial, Followed by Single-Arm Treatment of PRO 140

NCT02483078

HIV

COMPLETED PHASE2/PHASE3

An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study

NCT05271370

HIV-1-infection

TERMINATED PHASE2/PHASE3

PRO 140 in Treatment-Experienced HIV-1 Subjects

NCT03902522

HIV-1-infection

COMPLETED PHASE2/PHASE3

PRO 140 for Human Immunodeficiency Virus

NCT02438345

HIV

WITHDRAWN PHASE2

A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients

NCT01092104

HIV-1 Infection

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective is to assess the treatment strategy of using PRO 140 SC as long-acting, single-agent maintenance therapy for the chronic suppression of CCR5-tropic HIV-1 infection. In addition, the prognostic factors of therapeutic success of PRO 140 monotherapy will be evaluated.

The secondary objective of the trial is to assess the clinical efficacy, safety and tolerability parameters following substitution of combination antiretroviral therapy with weekly PRO 140 monotherapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Intervention Type DRUG

PRO 140 700 mg (175 mg/mL) SC injection per week

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PRO 140 (350 mg)

PRO 140 350 mg (175 mg/mL) SC injection per week

Intervention Type DRUG

PRO 140 (525 mg)

PRO 140 525 mg (175 mg/mL) SC injection per week

Intervention Type DRUG

PRO 140 (700 mg)

PRO 140 700 mg (175 mg/mL) SC injection per week

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Leronlimab Leronlimab Leronlimab

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males and females, age ≥18 years
2. Receiving combination antiretroviral therapy for last 24 weeks
3. No change in ART within last 4 weeks prior to Screening Visit
4. Subject has two or more potential alternative approved ART drug options to consider.
5. Exclusive CCR5-tropic virus at Screening Visit
6. Plasma HIV-1 RNA \< 50 copies/mL at Screening Visit
7. CD4 cell count of \> 200 cells/mm3 since initiation of anti-retroviral therapy
8. CD4 cell count of \> 350 cells/mm3 in preceding 24 weeks and at Screening Visit
9. Laboratory values at Screening of:

1. Absolute neutrophil count (ANC) ≥ 750/mm3
2. Hemoglobin (Hb) ≥ 10.5 gm/dL (male) or ≥ 9.5 gm/dL (female)
3. Platelets ≥ 75,000 /mm3
4. Serum alanine transaminase (SGPT/ALT) \< 5 x upper limit of normal (ULN)
5. Serum aspartate transaminase (SGOT/AST) \< 5 x ULN
6. Bilirubin (total) \< 2.5 x ULN unless Gilbert's disease is present or subject is receiving atazanavir in the absence of other evidence of significant liver disease
7. Creatinine ≤ 1.5 x ULN
10. Clinically normal resting 12-lead ECG at Screening Visit or, if abnormal, considered not clinically significant by the Principal Investigator.
11. Both male and female patients and their partners of childbearing potential must agree to use 2 medically accepted methods of contraception during the course of the study.
12. Willing and able to participate in all aspects of the study, including use of SC medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written informed consent.

Exclusion Criteria

1. CXCR4-tropic virus or dual/mixed tropic (R5X4) virus determined by the Trofile™ DNA Assay
2. Hepatitis B infection as manifest by the presence of Hepatitis B surface antigen (HBsAg)
3. Any active infection or malignancy requiring acute therapy (with the exception of local cutaneous Kaposi's sarcoma)
4. Laboratory test values ≥ grade 4 DAIDS laboratory abnormality.
5. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study
6. Unexplained fever or clinically significant illness within 1 week prior to the first study dose
7. Any vaccination within 2 weeks prior to the first study dose or during the study.
8. Subjects who have failed on a maraviroc containing regimen.
9. Subjects weighing \< 35kg
10. History of anaphylaxis to any oral or parenteral drugs
11. History of Bleeding Disorder or patients on anti-coagulant therapy
12. Participation in an experimental drug trial(s) within 30 days of the Screening Visit
13. Any known allergy or antibodies to the study drug or excipients
14. Treatment with any of the following:

1. Radiation or cytotoxic chemotherapy with 30 days prior to the screening visit
2. Immunosuppressants within 60 days prior to the screening visit
3. Immunomodulating agents (e.g., interleukins, interferons), hydroxyurea, or foscarnet within 60 days prior to the screening visit
4. Oral or parenteral corticosteroids within 30 days prior to the Screening Visit. Subjects on chronic steroid therapy \> 5 mg/day will be excluded with the following exception:

* Subjects on inhaled, nasal, or topical steroids will not be excluded
15. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No